Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but almost uniformly lethal complication of blood transfusion. There are no effective treatments for TA-GVHD, management of this complication focuses on prevention by irradiation of cellular blood components such as whole blood, red blood cells (RBCs), granulocytes and platelets are intended for susceptible recipients. In many cases, the presence of congenital immune deficiency in the transfusion recipient serves as a prerequisite to the development of TA-GVHD. TA-GVHD has been reported to occur in the absence of a recognized immune deficiency, particularly in situations where the blood donor is homozygous for human leukocyte antigens (HLA) for which the recipient is heterozygous. The minimum dose of lymphocytes required to cause TA-GVHD in humans is not known and it may be influenced by factors that are not likely to be fully known prior to transfusion. Recovery was attributed to treatment with OKT3 and cyclosporin A.
- Blood transfusion
- Human leukocyte antigens
- Transfusion-associated graft-versus-host disease
ASJC Scopus subject areas